BMC Cancer最新文献

{"title":"Clinical efficacy analysis of chemotherapy of isolated neck lymphatic metastasis in advanced epithelial ovarian cancer.","authors":"Hong Liu, Min Luo, Chunrong Peng, Xinghan Cheng, Dengfeng Wang, Jianming Huang, Guonan Zhang","doi":"10.1186/s12885-025-14399-z","DOIUrl":"10.1186/s12885-025-14399-z","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to retrospectively investigate the efficacy of chemotherapy for neck lymph node metastasis (NLNM) by determining the characteristics and survival of patients with isolated NLNMs metastases from epithelial ovarian carcinoma (EOC) at stage IV of the Federation of Gynecology and Obstetrics (FIGO).</p><p><strong>Methods: </strong>The clinicopathological characteristics and survival outcome of 24 cases with stage IV FIGO EOC with isolated NLNM were retrospectively analyzed between December 1, 2014, and November 30, 2021.</p><p><strong>Results: </strong>Among the 24 patients, 2 (8.3%) underwent primary debulking surgery (PDS), 21 (87.5%) received neoadjuvant chemotherapy(NACT) followed by interval debulking surgery (IDS), and 1 (4.2%) received chemotherapy alone. Additionally, 13 (54.2%) cases achieved abdominal R0 debulking, while 11(45.8%) cases achieved R1/R2 debulking. The chemotherapy response of NLNMs included complete response (8/24, 33.3%), partial response (15/24,62.5%), or stable disease (1/24,41.7%). None of the patients received resection or radiotherapy of NLNMs. Recurrence was observed in 15 (62.5%) patients, with only 2 experiencing recurrence of NLNMs. The median progression-free survival (PFS) and overall survival (OS) were 35 months and 48 months, respectively. R0 debulking led to a significantly longer PFS (not reached) and OS (57 months) compared to non-R0 debulking (PFS: 10 months, P = 0.001; OS: 22 months, P = 0.001). Interestingly, patients with EOC with lymphatic recurrence had better OS ( 57 months) than did those with abdominal or distant recurrence (OS: 29 months; P = 0.012).</p><p><strong>Conclusions: </strong>Chemotherapy is an effective treatment for neck lymph nodes metastasis, and a favorable response to chemotherapy could eliminate the necessity for NLNM resection or radiotherapy. Effective control of abdominal disease with surgery may be a critical factor in managing FIGO stage IV EOC patients with isolated NLMNs.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"969"},"PeriodicalIF":3.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.","authors":"Lin Gui, Zucheng Xie, Yan Qin, Peng Liu, Jianliang Yang, Xinrui Chen, Zhenyu Li, Ran Tao, Yuankai Shi","doi":"10.1186/s12885-025-14370-y","DOIUrl":"10.1186/s12885-025-14370-y","url":null,"abstract":"<p><strong>Objective: </strong>Abexinostat, an novel pan-histone deacetylase inhibitor, induces tumor apoptosis and demonstrates therapeutic potential in B cell non-Hodgkin lymphoma (NHL). This phase 1 study investigate the safety, pharmacokinetics (PK), and efficacy of abexinostat in Chinese patients with relapsed/refractory (r/r) B cell NHL.</p><p><strong>Methods: </strong>Patients with r/r B cell NHL received abexinostat orally at escalating doses of 40 mg twice daily (bis in die, BID), 60 mg BID, and 80 mg BID with a 4-h interval, for seven days followed by a 7-day drug-free interval. Patients took abexinostat once on 3 days before day 1 (D-3) of the first cycle in single dose period. If no dose limiting toxicity (DLT) occurred from D-3 to C1D1, the continuous dose period was started from C1D1, abexinostat was given BID. The Primary endpoints were safety and PK.</p><p><strong>Results: </strong>From April 13, 2020 to November 30, 2023, 12 r/r B cell NHL patients were enrolled, including 6 follicular lymphoma (FL), 5 diffuse large B cell lymphoma (DLBCL) and 1 mantle cell lymphoma (MCL). 11 patients received at least one dose abexinostat included in the safety set. No DLT were observed, 80 mg BID was the recommended phase 2 dose (RP2D). Most treatment emergent adverse events (TEAEs) were grade 1 or 2, and grade 3 TEAEs included thrombocytopenia (2/11, 18.2%) and hypertriglyceridemia (3/11, 27.3%). The median time to maximum concentration (T_max) was 0.5-1.0 h and the median terminal elimination half-life (T_1/2) was 2.56-8.31 h. Ten patients were included in full analysis set. The objective response rate (ORR) was 40.0% (4/10, 95% CI: 12.2-73.8), including 1 complete response and 3 partial response. The ORR was 50.0% (3/6, 95% CI: 11.8-88.2) of FL patients. The median progression-free survival and duration of response of FL were 8.38 months (95% CI: 1.05-NE) and 7.82 months(95% CI: 7.33-NE), respectively. The OS was not reached.</p><p><strong>Conclusions: </strong>Abexinostat showed favorable tolerability with no DLT in Chinese patients with r/r B cell NHL. The RP2D was 80 mg BID. The plasma concentration was dose-proportional manner. The PK result demonstrated that BID \"one week on, one week off\" administration is reasonable. Promising anti-tumor activity were seen in these patients population. This result support further investigation.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov (NCT04024696). Date of registration: 18 July 2019.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"967"},"PeriodicalIF":3.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of Adiponectin and Leptin in Colorectal Cancer and Adenoma: a systematic review and meta-analysis.","authors":"Iman Elahi Vahed, Mahsa Moshgelgosha, Abdolmajid Kor, Mona Minadi, Faezeh Ebrahimi, Aylar Azhdarian, Mobina Arjmandi, Aida Alamdar, Maede Zare, Niloufar Shabani, Hossein Soltaninejad, Mohammad Rahmanian","doi":"10.1186/s12885-025-14362-y","DOIUrl":"10.1186/s12885-025-14362-y","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer ranks as the third most frequently diagnosed cancer globally. Adipokines, including adiponectin and leptin, are believed to play a vital role in the development and progression of tumors. This study aimed to clarify the association between circulating adiponectin and leptin concentrations and the risk of colorectal cancer and adenoma.</p><p><strong>Methods: </strong>A detailed literature review was conducted in different databases, including Google Scholar, Web of Science, Scopus, and PubMed. Articles measuring serum concentrations of adiponectin and leptin in colorectal adenoma or cancer patients were analyzed. Pooled odds ratios (ORs) and their related 95% confidence intervals (CIs) were estimated through a random-effects meta-analysis.</p><p><strong>Results: </strong>In total, 30 articles were analyzed. According to the meta-analysis, higher adiponectin concentrations were inversely linked to a reduced CRC risk (OR: 0.85, 95% CI: 0.74-0.96), particularly in men. However, no notable connection was detected between higher leptin concentrations and risk of CRC (OR: 1.12, 95% CI: 0.96-1.31). In subgroup analyses, BMI adjustment reinforced the negative association between higher adiponectin levels and risk of CRC, while insulin adjustment yielded non-significant results. Additionally, higher leptin levels revealed a meaningful relationship with colorectal adenoma risk (OR: 1.39, 95% CI: 1.06-1.84), whereas higher levels of adiponectin were not significantly linked to adenoma (OR: 0.79, 95% CI: 0.46-1.36).</p><p><strong>Conclusion: </strong>According to this meta-analysis, elevated adiponectin concentrations may play a protective role against CRC, while leptin could potentially contribute to an elevated colorectal adenoma risk. Further studies are required to explore the potential mechanisms underlying adipokine-mediated colorectal carcinogenesis.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"968"},"PeriodicalIF":3.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CircSLC22A3 inhibits the invasion and metastasis of ESCC via the miR-19b-3p/TRAK2 axis and by reducing the stability of m⁶A-modified ACSBG1 mRNA.","authors":"Yingjie Pan, Hang Yang, Jiayi Zhang, Ruolan Zhang, Yun Liu, Jun Bie, Qiaoling Chen, Yan Qiao, Kang Liu, Guiqin Song","doi":"10.1186/s12885-025-14390-8","DOIUrl":"10.1186/s12885-025-14390-8","url":null,"abstract":"<p><strong>Background: </strong>Esophageal squamous cell carcinoma (ESCC) is a major contributor to cancer-related deaths, driven by its invasive and metastatic nature. Circular RNAs (circRNAs) are increasingly recognized as regulators of cancer progression, primarily through miRNA sponging and interactions with RNA-binding proteins. Their dysregulation has been linked to the development of in various cancers. The present study aimed to investigate the potential involvement of circSLC22A3 in the pathogenesis of ESCC.</p><p><strong>Methods: </strong>CircSLC22A3 expression in ESCC tissues and cells was analyzed using transcriptome sequencing and RT-qPCR. Its circular structure was validated through Sanger sequencing, agarose gel electrophoresis, RNase R digestion, and random priming assays. Subcellular localization was determined by nucleoplasmic separation and fluorescence in situ hybridization (FISH). Clinical correlations were assessed via tissue microarrays. Functional roles of circSLC22A3 in ESCC progression were investigated through in vitro and in vivo assays. Downstream miR-19b-3p and target gene TRAK2 were screened by bioinformatics analysis and RT-qPCR, with binding confirmed via luciferase reporter assays. RNA pulldown combined with RNA immunoprecipitation (RIP) identified IGF2BP1 as a circSLC22A3-interacting protein. RNA-seq and RT-qPCR revealed ACSBG1 as a key downstream effector. IGF2BP1-mediated m⁶A modification of ACSBG1 was mapped by MeRIP-seq and RIP, with mRNA stability assessed via Actinomycin D assay. ACSBG1 expression and biological function in ESCC were confirmed by immunohistochemistry, RT-qPCR, and functional assays.</p><p><strong>Results: </strong>Significant downregulation of circSLC22A3 was observed in both ESCC tissues and cell lines. Overexpression of circSLC22A3 significantly reduced ESCC cells' migration and invasion capabilities. Mechanistic investigation revealed that circSLC22A3 played a pivotal role in the invasion and metastasis of esophageal cancer through distinct pathways. On one hand, circSLC22A3 functioned as a miR-19b-3p sponge to augment trafficking kinesin protein 2 (TRAK2) expression, while, on the other hand, circSLC22A3 formed a protein-RNA complex with IGF2BP1, resulting in the degradation of acyl-CoA synthetase bubblegum family member 1 (ACSBG1) mRNA through the recognition of m⁶A modification, thereby suppressing invasion and metastasis of ESCC.</p><p><strong>Conclusions: </strong>The present study identified circSLC22A3 as a new tumor suppressor that inhibited ESCC progression through both the circSLC22A3/ miR-19b-3p/ TRAK2 and circSLC22A3/ IGF2BP1/ ACSBG1 axes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"971"},"PeriodicalIF":3.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NAT10 inhibits the pyroptosis of laryngeal squamous cell carcinoma through ac4C modification of ELANE mRNA.","authors":"Yafang Yu, Jianwen Yan","doi":"10.1186/s12885-025-14352-0","DOIUrl":"10.1186/s12885-025-14352-0","url":null,"abstract":"<p><strong>Background: </strong>Laryngeal squamous cell carcinoma (LSCC) is the most common type of head and neck malignancy. NAT10 is a catalytic enzyme for ac4C and is involved in the progression of a variety of cancers. This study aimed to explore the effects and potential mechanisms of NAT10 in LSCC.</p><p><strong>Methods: </strong>Pyroptosis was assessed by measuring the release of lactic dehydrogenase, pyroptosis rate, and pyroptosis-related proteins. The RNA and protein levels were detected by quantitative real-time PCR and western blot, respectively. Potential mechanisms were validated using flow cytometry, ac4C dot blot, methylated RNA immunoprecipitation (MeRIP), RIP, and Dual-Luciferase Reporter Assay experiments.</p><p><strong>Results: </strong>The result showed that the levels of NAT10 in LSCC tissues and cells were elevated and positively correlated with tumor grading and clinical staging. Knockdown of NAT10 promoted the pyroptosis of LSCC cells. NAT10 directly interacted with ELANE, suppressed the stability of the ELANE mRNA. NAT10 inhibited pyroptosis in LSCC by downregulating the ELANE expression in vivo and in vitro.</p><p><strong>Conclusion: </strong>NAT10 inhibited the pyroptosis of LSCC cells and contributed to LSCC progression by suppressing ELANE mRNA stability in ac4C modification manner, indicating that the NAT10-ac4C-ELANE axis might be a potential target for LSCC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"970"},"PeriodicalIF":3.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyogenic liver abscess following biliary stent placement in pancreatic cancer patients: a retrospective case series.","authors":"Dongxue Geng, Nan Lv, Yi Miao","doi":"10.1186/s12885-025-14377-5","DOIUrl":"10.1186/s12885-025-14377-5","url":null,"abstract":"<p><p>Biliary stent placement is widely used in clinical, especially in patients with pancreatic cancer complicated with obstructive jaundice. Pyogenic liver abscess (PLA) is a severe complication following biliary stent placement which predominantly occurs in the right lobe of the liver, with an incidence rate ranging from 4.3% to 13.5% and a mortality rate up to 30%. It is related to the following mechanisms: retrograde bacterial infection; bile stasis and increased bile duct pH; stent-related bile duct injury; biofilm formation; immune system suppression. The main causative pathogens are gram-negative bacilli, particularly Escherichia coli and Klebsiella pneumoniae. The combination of antibiotic therapy and percutaneous transhepatic abscess drainage is the main treatment option.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"965"},"PeriodicalIF":3.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study.","authors":"Stéphane Renaud, Paul Casabianca, Pauline Diez-Andreu, Mélanie Chartier, Anne-Françoise Gaudin, Françoise Bugnard, Stève Bénard, François-Emery Cotté, Christos Chouaid","doi":"10.1186/s12885-025-14334-2","DOIUrl":"10.1186/s12885-025-14334-2","url":null,"abstract":"<p><strong>Introduction: </strong>Surgery is the standard of care for eligible patients with localized or stage IIIA locally advanced non-small cell lung cancer (NSCLC) current guidelines recommend the most conservative surgeries possible. The aim of this study was to bring new real-world data on resected NSCLC epidemiology, management, and survival outcomes in patients with resected non-metastatic NSCLC.</p><p><strong>Materials and methods: </strong>This is a descriptive, non-interventional, national, retrospective claims study using data from the French National Hospitalization Database (PMSI) describing the management of patients with non-metastatic NSCLC who underwent a first lung resection (LR) between 2015 and 2019. Patients with LR performed in 2015 were followed from LR until the last registered hospital care or in-hospital death. Five-year disease-free survival (DFS [i.e., time from LR to first recurrence or death]) and overall survival (OS) were assessed.</p><p><strong>Results: </strong>The rate of patients with non-metastatic NSCLC and a first LR between 2015 and 2019 increased by an average of 4.5% per year (8,688 in 2015 vs. 10,330 in 2019). Lobectomy (79.8% vs. 84.9%) and video-assisted thoracoscopic surgery (29.6% vs. 46.4%) became more frequent. Five-year DFS was 33.7% [95%CI 29.8-37.6%] following infralobar resection, 52.3% [51.0-53.5%] after lobectomy, 42.3% [36.9-47.5%] after bilobectomy, and 33.6% [30.0-37.2%] after pneumonectomy. Respective five-year OS from LR were 58.4% [54.1-62.4], 70.2% [69.0-71.3], 59.3% [53.7-64.4], and 46.3% [42.3-50.2].</p><p><strong>Conclusions: </strong>This study highlights the increasing trend toward conservative and less invasive surgeries in resected NSCLC. Type of LR can be used as an indirect marker of disease expansion, with poorer survival outcomes in case of extensive surgeries.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"966"},"PeriodicalIF":3.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition.","authors":"Yanan Jiang, Donghui Xing, Xiang He, Wenqi Wu, Hong Xu, Huimeng Sun, Yixin Zhai, Kaiping Luo, Zhigang Zhao","doi":"10.1186/s12885-025-14257-y","DOIUrl":"10.1186/s12885-025-14257-y","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematopoietic malignancy, necessitating the exploration of innovative therapeutic approaches. Targeting epigenetic mechanisms has emerged as a promising avenue for cancer treatment. EP300 belongs to the KAT3 family of histone/non-histone lysine acetyltransferases, regulating gene expression by acetylating H3K27. However, the role of EP300 and its potential as a targeted therapy in DLBCL remains unknown.</p><p><strong>Methods: </strong>Public datasets were collected to evaluate the expression and clinical significance of epigenetic modification-related genes in patients with DLBCL. Flow cytometry, colony formation, and western blotting were conducted to investigate the function of EP300. CCK8, proliferation, cell cycle, and apoptosis assays, as well as experiments in tumor-bearing mouse models were conducted to determine the therapeutic effect of the EP300 inhibitor A485 alone or in combination with the XPO1 inhibitor KPT8602. RNA-seq was used to investigate the molecular mechanisms underlying the inhibition of DLBCL development by A485.</p><p><strong>Results: </strong>EP300 is frequently overexpressed in DLBCL and is associated with poor prognosis, highlighting its potential role in lymphoma progression. In this study, we found that A485, a novel small-molecule inhibitor targeting the conserved histone acetyltransferase (HAT) domain of EP300, significantly reduced H3K27Ac levels and demonstrated potent antitumor effects in DLBCL cells, both in vitro and in vivo. Furthermore, we showed that A485 attenuated DLBCL progression by inhibiting the MYC and E2F1 pathways. Notably, the combination of A485 with the XPO1 inhibitor KPT8602 produced synergistic anti-lymphoma in vitro and in vivo effects in DLBCL cell lines. This combination therapy resulted in enhanced tumor suppression in a DLBCL xenograft model with minimal toxicity. These findings suggested that targeting EP300, particularly in conjunction with XPO1 inhibition, could represent a promising therapeutic strategy for DLBCL treatment.</p><p><strong>Conclusions: </strong>Our study elucidated that EP300 inhibition, especially in combination with XPO1 blockade, could serve as a promising therapeutic strategy for the treatment of DLBCL.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"955"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating cancer care in Cameroon: a theory-guided inquiry on patient experiences at Mbingo Baptist Hospital.","authors":"Glenn Mbah Afungchwi, Eric Makiyighome Tum, Laurie Elit","doi":"10.1186/s12885-025-14338-y","DOIUrl":"10.1186/s12885-025-14338-y","url":null,"abstract":"<p><strong>Background: </strong>Cancer remains a leading cause of morbidity and mortality globally, with rising incidence rates, especially in low- and middle-income countries (LMICs). This burden is pronounced in Sub-Saharan Africa (SSA), where Cameroon faces escalating cancer challenges, primarily due to inadequate healthcare infrastructure and limited access to early detection and treatment. The study aimed to explore the experiences of cancer patients at Mbingo Baptist Hospital in Cameroon in Cameroon, focusing on the barriers to obtaining quality diagnosis, treatment, and follow-up care, and to examine the impact of these challenges on their physical, emotional, and social well-being.</p><p><strong>Methods: </strong>This study employed a qualitative descriptive design, conducting in-depth interviews with eleven cancer patients in December 2023 and January 2024. Participants were selected using purposive sampling, and data were analyzed using thematic analysis to identify key barriers in the cancer care pathway. The biopsychosocial model guided the exploration of patients' experiences, capturing the interplay between biological, psychological, and social dimensions of their healthcare journey.</p><p><strong>Results: </strong>The analysis revealed significant delays in diagnosis, substantial financial burdens, and emotional and psychological distress among patients. Key themes identified include challenges in the diagnosis and treatment processes, the financial impact of cancer care, emotional and psychosocial repercussions, and difficulties in accessing healthcare services. Despite facing these obstacles, patients also reported instances of resilience and support within their families and communities.</p><p><strong>Conclusion: </strong>The study underscores the urgent need for systemic improvements in cancer care in Cameroon and similar contexts. Enhancing healthcare infrastructure, broadening financial protection, and fostering awareness and early detection are imperative. Additionally, integrating a holistic care approach that considers the biopsychosocial aspects of patient health is crucial for improving outcomes. Addressing these recommendations requires collaborative efforts from governmental and non-governmental organizations, healthcare providers, and the international community to tailor cancer control strategies to the unique needs of LMICs, aiming to alleviate the cancer burden and enhance patient quality of life.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"958"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.","authors":"Hongquan Xing, Cong Wu, Weichang Yang, Shanshan Cai, Xinyi Zhang, Xiaoqun Ye","doi":"10.1186/s12885-025-14363-x","DOIUrl":"10.1186/s12885-025-14363-x","url":null,"abstract":"<p><strong>Background: </strong>Tracheal, bronchial, and lung (TBL) cancer presents significant health challenges for individuals aged 70 and older. However, comprehensive insights into the epidemiological patterns of and risk factors for TBL cancer in this population remain limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer patients aged ≥ 70 years from 1990-2021.</p><p><strong>Methods: </strong>The incidence, mortality, and disability-adjusted life years (DALYs) for TBL cancer patients aged ≥ 70 years from 1990-2021 were obtained from the 2021 Global Burden of Disease study. Global trends were stratified age, sex, and sociodemographic index (SDI). Decomposition analysis identified the primary drivers of burden changes, and a global risk attribution analysis was conducted. The Bayesian Age‒Period‒Cohort (BAPC) model forecasted trends over the next 14 years. The analyses were performed with Joinpoint software and the R software.</p><p><strong>Results: </strong>From 1990-2021, the ASIRs, ASMRs, and ASDRs of TBL cancer among patients ≥ 70 years increase significantly, mainly due to aging and population growth. In the precision medicine era (2015-2021), these indicators for both sexes and males have declined, but the burden among females has increased. The burden varies across regions, with the incidence of TBL cancer increasing more severely in middle-SDI regions, East Asia, and western sub-Saharan Africa, whereas high-SDI regions have shown a decline after peaking. Although the DALY proportion of smoking decreased, it was still the main cause of TBL cancer. However, the burden of environmental particulate pollution has increased. The BAPC model predicted that in the future, the ASIR, ASMR, and ASDR for males and both sexes would decrease, whereas these indicators would either remain stable or increase among females.</p><p><strong>Conclusions: </strong>The burden of TBL cancer is increasing significantly among patients aged ≥ 70 years. Despite new hopes and approaches from precision medicine, environmental and behavioral factors still critically influence the TBL cancer burden. Future strategies could enhance subgroup-specific management and promote effective control of known risk factors.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"954"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}